<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="rapid-communication"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Curr</journal-id><journal-title-group><journal-title>PLoS Currents</journal-title></journal-title-group><issn pub-type="epub">2157-3999</issn><publisher><publisher-name>Public Library of Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20029659</article-id><article-id pub-id-type="pmc">2768144</article-id><article-id pub-id-type="knolid">http://knol.google.com/k/-/-/1vezxg5atvojv/2</article-id><article-id pub-id-type="art-access-id">PMC2768144</article-id><article-id pub-id-type="doi">10.1371/currents.RRN1121</article-id><article-categories><subj-group subj-group-type="heading"><subject>Influenza</subject></subj-group></article-categories><title-group><article-title>Targeted vs. systematic early antiviral treatment against A(H1N1)v influenza with neuraminidase inhibitors in patients with influenza-like symptoms: Clinical and economic impact</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Deuffic-Burban</surname><given-names>Sylvie</given-names></name><xref ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name><surname>Lenne</surname><given-names>Xavier</given-names></name><xref ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Dervaux</surname><given-names>Benoit</given-names></name><xref ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Julien Poissy</surname></name><xref ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Lemaire</surname><given-names>Xavier</given-names></name><xref ref-type="aff">&#x000b6;</xref></contrib><contrib contrib-type="author"><name><surname>Sloan</surname><given-names>Caroline</given-names></name></contrib><contrib contrib-type="author"><name><surname>Carrat</surname><given-names>Fabrice</given-names></name><xref ref-type="aff">#</xref></contrib><contrib contrib-type="author"><name><surname>Desenclos</surname><given-names>Jean-Claude</given-names></name><!--Directeur scientifique--><xref ref-type="aff">**</xref></contrib><contrib contrib-type="author"><name><surname>Delfraissy</surname><given-names>Jean-Francois</given-names></name><xref ref-type="aff">&#x02020;&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Yazdanpanah</surname><given-names>Yazdan</given-names></name><xref ref-type="aff">&#x02021;&#x02021;</xref></contrib></contrib-group><aff><sup>*</sup>INSERM U795 and EA2694, Facult&#x000e9; de M&#x000e9;decine de Lille, Lille, France; <sup>&#x02020;</sup>CRESGE-LEM UMR 8179, Universit&#x000e9; Catholique de Lille, Lille, France; <sup>&#x02021;</sup>EA2694, Facult&#x000e9; de M&#x000e9;decine de Lille, Lille, France; <sup>&#x000a7;</sup>Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier Dron, Tourcoing, France; <sup>&#x000b6;</sup>Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier Dron, Tourcoing, France; Service de Medecine Interne, Centre Hospitalier de Douai, France; <sup>#</sup>INSERM UMR-S 707, UPMC, Paris, France; Unit&#x000e9; de Sant&#x000e9; Publique, AP-HP, H&#x000f4;pital Saint-Antoine F-75012; <sup>**</sup>Institut de Veille Sanitaire (InVS), Saint Maurice, France; <sup>&#x02020;&#x02020;</sup>Service de M&#x000e9;decine Interne et des Maladies Infectieuses, AP-HP, H&#x000f4;pital Bic&#x000ea;tre, Le Kremlin-Bic&#x000ea;tre, France and <sup>&#x02021;&#x02021;</sup>EA2694, Facult&#x000e9; de M&#x000e9;decine de Lille, Lille, France; Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier Dron, Tourcoing, France</aff><pub-date pub-type="epub"><day>27</day><month>10</month><year>2009</year></pub-date><volume>1</volume><elocation-id>RRN1121</elocation-id><history><date date-type="created"><day>22</day><month>10</month><year>2009</year></date><date date-type="accepted"><day>26</day><month>10</month><year>2009</year></date></history><permissions><license><license-p>This research note is distributed under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons
						Attribution 3.0 License.</ext-link></license-p></license></permissions><abstract><!--WRITE-PARA--><p id="p1">Capitalizing on available data, we used a decision model to estimate the clinical and economic outcomes associated with early initiation of treatment with neuraminidase inhibitors in all patients with influenza-like illnesses ( ILI ) (systematic strategy) vs. only those at high risk of complications (targeted strategy). Systematic treatment of ILI during an A(H1N1)v influenza epidemic wave is both effective and cost-effective. Patients who present to care with ILI during an A(H1N1)v influenza epidemic wave should initiate treatment with neuraminidase inhibitors, regardless of risk status. Administering neuraminidase inhibitors between epidemic waves, when the probability of influenza is low, is less effective and cost-effective.</p></abstract></article-meta></front><body><sec id="sec1"><title>
        <bold> Introduction</bold>
      </title><!--WRITE-PARA--><p id="p2">On April 29 2009, the World Health Organization (WHO) announced that the A(H1N1) virus (A(H1N1)<italic>v</italic>), which is composed of a unique combination of gene segments never before observed in human or swine influenza viruses, was spreading rapidly across the globe <xref ref-type="bibr" rid="ref-2928398134">[1]</xref>. Since April, A(H1N1)<italic>v</italic> influenza has spread from an initial outbreak in Mexico and the southern United States to a total of 150 countries in October 2009 <xref ref-type="bibr" rid="ref-482322842">[2]</xref>
        <xref ref-type="bibr" rid="ref-2251133444">[3]</xref>
        <xref ref-type="bibr" rid="ref-4221853969">[4]</xref>
        <xref ref-type="bibr" rid="ref-748790577">[5]</xref>
        <xref ref-type="bibr" rid="ref-2310951653">[6]</xref>
        <xref ref-type="bibr" rid="ref-4290000922">[7]</xref>. Of the roughly 375,000 laboratory-confirmed cases of A(H1N1)<italic>v</italic> influenza worldwide, over 4,500 were fatal <xref ref-type="bibr" rid="ref-716910853">[8]</xref>.
      </p><!--WRITE-PARA--><p id="p3">A(H1N1)<italic>v</italic> can be treated with neuraminidase inhibitors such as oseltamivir and zanamivir. The virus is susceptible to these drugs in the first 48 hours of infection. In all high-income countries except for the United Kingdom, early antiviral treatment with neuraminidase inhibitors is only recommended for A(H1N1)<italic>v</italic>-infected patients who have severe symptoms or underlying conditions associated with a high risk of developing seasonal influenza complications <xref ref-type="bibr" rid="ref-2676606313">[9]</xref>
        <xref ref-type="bibr" rid="ref-3062049286">[10]</xref>
        <xref ref-type="bibr" rid="ref-309199049">[11]</xref>
        <xref ref-type="bibr" rid="ref-1623490564">[12]</xref>
        <xref ref-type="bibr" rid="ref-4002487091">[13]</xref>. These recommendations are based on our current understanding of seasonal human influenza. However, recent data have shown that, unlike with seasonal influenza <xref ref-type="bibr" rid="ref-4114420138">[14]</xref>, a high proportion of severe and fatal A(H1N1)<italic>v</italic> complications occur in previously healthy young people <xref ref-type="bibr" rid="ref-150613430">[15]</xref>
        <xref ref-type="bibr" rid="ref-3809112805">[16]</xref>
        <xref ref-type="bibr" rid="ref-669132870">[17]</xref>
        <xref ref-type="bibr" rid="ref-1521450404">[18]</xref>
        <xref ref-type="bibr" rid="ref-3491413473">[19]</xref>. At the National Institute of Respiratory Diseases in Mexico City for instance, of the first 18 patients who were hospitalized for pneumonia and laboratory-confirmed A(H1N1)<italic>v </italic>influenza, only eight had preexisting medical conditions <xref ref-type="bibr" rid="ref-3809112805">[16]</xref>. Similarly, of the first 32 patients who were admitted to intensive care units (ICU) with A(H1N1)<italic>v </italic>influenza in Spain, 15 had no preexisting medical conditions <xref ref-type="bibr" rid="ref-1521450404">[18]</xref>. In a recent analysis that used complementary data from two cities in the United States, Presanis <italic>et al</italic>. found a higher symptomatic case-fatality ratio in the non-elderly adult group than in the elderly group (0.136% 18-64 years <italic>vs</italic>. 0.028% &#x0003e;65 years)&#x000a0;<xref ref-type="bibr" rid="ref-669132870">[17]</xref>. Given these data and the decreased efficacy of neuraminidase inhibitors &#x0003e;48 hours after the onset of symptoms <xref ref-type="bibr" rid="ref-336100170">[20]</xref>
        <xref ref-type="bibr" rid="ref-492377043">[21]</xref>, policy makers have to decide whether to recommend treating all patients who present to care with influenza-like illnesses (ILI), or just those at high risk of influenza complications.&#x02028;
      </p><!--WRITE-PARA--><p id="p4">Several prevention and treatment options for A(H1N1)<italic>v</italic> influenza are currently available. However, the data needed to make an informed decision are incomplete and results of clinical trials and/or epidemiological cohort studies will not be available in time to curb this rapidly spreading disease. Decision-analysis methods provide a systematic approach to synthesizing existing data and quantifying the trade-offs for alternative options. Capitalizing on available data to date, we used a decision model to estimate during an epidemic wave the clinical and economic outcomes associated with early initiation of antiviral treatment with neuraminidase inhibitors in all symptomatic patients <italic>vs</italic>. only those at high risk of influenza complications.</p></sec><sec id="sec2"><title>
        <bold>Material and methods</bold>
      </title><sec id="sec3"><title>Study design</title><!--WRITE-PARA--><p id="p5">We built a decision model to compare two antiviral treatment strategies of A(H1N1)<italic>v</italic> influenza management during an epidemic wave in France: early treatment with neuraminidase inhibitors in patients who present to care with ILI and are at high risk of complications, as currently recommended in France (targeted strategy) <xref ref-type="bibr" rid="ref-1623490564">[12]</xref>, <italic>vs</italic>. early treatment with neuraminidase inhibitors in all patients who present to care with ILI (systematic strategy).</p><!--WRITE-PARA--><p id="p6">We evaluated each strategy in a cohort of 64,300,000 people, the size of the French population in 2009. The incidence of the simulated disease follows the trajectory of a unique pandemic A(H1N1)<italic>v</italic> influenza wave. Model outcomes include mortality, overall hospitalizations, ICU admissions, cost, and cost-effectiveness. Costs consisted only of direct medical costs. Cost-effectiveness is defined as the additional cost of one strategy compared to another strategy divided by its additional clinical benefit <xref ref-type="bibr" rid="ref-156585246">[22]</xref>
          <xref ref-type="bibr" rid="ref-1416903824">[23]</xref>. Outcomes were assessed from the French health care provider perspective. Clinical benefits, expressed in years of life gained (YLG), were discounted at 3% per year. Costs, expressed in 2009 euros (&#x020ac;1.00 = US$1.48 = &#x000a3;0.91 on 24 September 2009) were not discounted, because all costs are incurred in the first year. 
        </p></sec><sec id="sec4"><title>Model structure (Figure 1)</title><!--WRITE-PARA--><p id="p7">The root node of the decision tree divides into two branches that represent each treatment strategy. Patients who present with ILI can be at high or low risk of developing complications from A(H1N1)<italic>v</italic>. Patients can follow various pathways, depending on the probability of the following events: (i) development of symptomatic ILI; (ii) presentation to care given symptomatic ILI; (iii) A(H1N1)<italic>v</italic> influenza given presentation to care with ILI; (iv) hospitalization given presentation to care and diagnosis of A(H1N1)<italic>v</italic>; (v) ICU admission given hospitalization; and (vi) death given ICU admission. </p><!--WRITE-PARA--><p id="p8">In the targeted strategy, patients with ILI initiate antiviral treatment if they are hospitalized or if they are at high risk of complications. Transition probabilities for these patients were derived from the A(H1N1)<italic>v</italic> influenza epidemic in New Zealand, where targeted antiviral treatment is currently recommended <xref ref-type="bibr" rid="ref-3062049286">[10]</xref>. These probabilities therefore incorporate the efficacy of antiviral treatment in high-risk patients. In the systematic strategy, patients who present to care with ILI &#x0003c;48 hours after the onset of symptoms and are at low risk of complications also receive treatment. We assume that a proportion of these patients present to care &#x0003e;48 hours after the onset of symptoms and do not benefit from antiviral treatment. Treatment efficacy is defined as the percent reduction in hospitalizations among patients with ILI who present to care &#x0003c;48 hours after the onset of symptoms. In both strategies, patients initiate oseltamivir treatment without confirmatory testing for A(H1N1)<italic>v</italic> influenza. The mean daily dose of oseltamivir is 30 mg x2 for infants aged &#x0003c;one year, 45mg x2 for children aged 1-12 years, and 75 mg x2 for children and adults aged &#x0003e;12 years.</p></sec><sec id="sec5"><title>Input data</title><!--WRITE-PARA--><p id="p9">According to French recommendations on antiviral treatment use in patients with A(H1N1)<italic>v</italic> influenza, high-risk patients include: patients aged &#x0003e;65 years; infants aged &#x0003c;one year; pregnant women; and patients with chronic respiratory diseases, chronic cardiovascular diseases, diabetes, obesity and immunosuppression <xref ref-type="bibr" rid="ref-353580865">[24]</xref>. The elderly and infant population in France represents 17.8% of the overall population <xref ref-type="bibr" rid="ref-1898167246">[25]</xref>. The number of pregnant women at time <italic>t</italic> was estimated from the average number of births in France over 9 months in 2008, and represents 0.9% of the French population <xref ref-type="bibr" rid="ref-1898167246">[25]</xref>. We estimated the number of patients aged &#x0003c;65 years who suffer from chronic respiratory disease, chronic cardiovascular disease, diabetes, obesity and immunosuppression from data on chronic disease treatment reimbursements in the French national health system. These patients represent 3% of the French population <xref ref-type="bibr" rid="ref-1339437522">[26]</xref>. Overall, in a population of mean age 40 years, 23% of people were estimated to be at high risk of developing influenza complications.</p><!--WRITE-PARA--><p id="p10">The characteristics and outcomes of the A(H1N1)<italic>v</italic> influenza epidemic in the targeted strategy are largely based on data from the 11-week A(H1N1)<italic>v</italic> influenza epidemic in New Zealand, where the influenza season is nearly over (Table 1) <xref ref-type="bibr" rid="ref-3335166991">[27]</xref>. In New Zealand, 34.9% of the overall population developed ILI, 5.5% of symptomatic people presented to care, and 21.5% of patients who presented to care were diagnosed with A(H1N1)<italic>v</italic> influenza. The attack rate was 7.5%. Among patients who presented to care with A(H1N1)<italic>v</italic> influenza, 5.5% were hospitalized. Using data from Germany, we estimated that high-risk patients were 2.7 times more likely to be hospitalized than low-risk patients <xref ref-type="bibr" rid="ref-150613430">[15]</xref>. In a recent analysis, Jain <italic>et al</italic>. did not find an increased risk of ICU admission or death in patients with underlying medical conditions <xref ref-type="bibr" rid="ref-3491413473">[19]</xref>. Therefore, the probability of being admitted to the ICU given hospitalization (12%) and the probability of death given ICU admission (14%) was assumed to be the same in both low- and high-risk groups. We varied all of these values in the sensitivity analysis.</p><!--WRITE-PARA--><p id="p11">When low-risk patients with A(H1N1)<italic>v</italic> influenza presented to care &#x0003c;48 hours after the onset of symptoms, antiviral treatment reduced the probability of hospitalization by 60%, as reported by Kaiser <italic>et al</italic>. <xref ref-type="bibr" rid="ref-3555451527">[28]</xref>. We estimated the proportion of low-risk patients who present to care &#x0003c;48 hours after the onset of symptoms from an analysis of the first A(H1N1)<italic>v</italic> influenza cases in Germany <xref ref-type="bibr" rid="ref-150613430">[15]</xref>. This study showed that the average time between onset of symptoms and antiviral treatment initiation in 1,810 patients was 2.2 days, with a decreasing trend from week 28 (4.0 days) to week 32 (2.0 days) of the analysis. We assumed that 25% of low-risk patients who presented to care with ILI started treatment on the first day of symptoms and 25% started treatment on the second day. The last 50% of patients presented to care too late to benefit from antiviral treatment. Furthermore, some studies have suggested that the beginning of symptoms is difficult to recall accurately in 49% of cases of influenza because of the insidious onset of the disease <xref ref-type="bibr" rid="ref-429906310">[29]</xref>
          <xref ref-type="bibr" rid="ref-479242327">[30]</xref>. We assumed that 49% of patients who initiated treatment on the second day did not recall the onset of their symptoms accurately, and that half of them presented to care &#x0003e;48 hours after the onset of symptoms. The proportion of patients who presented to care and initiated treatment &#x0003c;48 hours after the onset of symptoms was thus 43.9% ([25% + 25%] - [25% x 50% x 49%]).
        </p><!--WRITE-PARA--><p id="p12">Clinic visit costs are from the French Nomenclature G&#x000e9;n&#x000e9;rale des Actes Professionels <xref ref-type="bibr" rid="ref-2471305942">[31]</xref> and drug costs are from national medication rates <xref ref-type="bibr" rid="ref-539055477">[32]</xref>. The cost of a primary care clinic visit was &#x020ac;21 and five-day oseltamivir treatment costs ranged from &#x020ac;13 to &#x020ac;25, depending on dosage. We derived inpatient costs for ILI from 2006 French hospital information system (Programme de M&#x000e9;dicalisation des Syst&#x000e8;mes d&#x02019;Information) data <xref ref-type="bibr" rid="ref-539572061">[33]</xref>
          <xref ref-type="bibr" rid="ref-4265247156">[34]</xref>, which differentiate ICU admissions from regular inpatient visits <xref ref-type="bibr" rid="ref-415459089">[35]</xref>
          <xref ref-type="bibr" rid="ref-1046517456">[36]</xref>. We considered costs for all patients assigned to diagnostic-related group (DRG) 04M13Z (pulmonary edema and respiratory distress) and international classification of diseases (ICD)-10 category J96.0 (acute respiratory failure) <xref ref-type="bibr" rid="ref-1657402311">[37]</xref>. The average length of inpatient stay was four days and was derived from the French A(H1N1)<italic>v</italic> influenza surveillance system, which was set up in the spring of 2009 <xref ref-type="bibr" rid="ref-668597037">[38]</xref>.
        </p></sec><sec id="sec6"><title>Sensitivity analysis</title><!--WRITE-PARA--><p id="p13">In univariate sensitivity analysis, we varied key parameters over a wide range of reasonablevalues to evaluate the impact of data uncertainties on our overall conclusions. First, we varied the mean age of the A(H1N1)<italic>v</italic>-infected population, the proportion of patients at high risk of influenza complications, and the A(H1N1)<italic>v</italic> attack rate. Varying the probability of presentation to care with ILI without varying the probability of A(H1N1)<italic>v</italic> influenza given ILI allowed us to vary the attack rate. Second, we varied the probability of presentation to care with ILI in both strategies to evaluate the impact of higher overall rates of presentation to care in France compared to New Zealand. We also increased this probability among low-risk patients in the systematic strategy without changing the targeted strategy, to test the hypothesis that universal antiviral use might encourage patients to seek care. In this scenario, we assumed that none of the additional patients developed complications or required medical care. Third, we lowered the probability of hospitalization, increased the difference in ICU admission rates between low- and high-risk patients, and varied the rates and duration of hospitalizations and ICU admissions. Finally, we varied the proportion of patients initiating antiviral treatment &#x0003c;48 hours after the onset of symptoms, as well as oseltamivir efficacy (Table 1).</p><!--WRITE-PARA--><p id="p14">We conducted two two-way sensitivity analyses. We performed the first to investigate the impact of differences in resource utilization among patients with ILI in France and in New Zealand. In this sensitivity analysis, we increased the probability of presentation to care with ILI and decreased the probability of hospitalization given presentation to care. According to available data on resource utilization related to seasonal influenza <xref ref-type="bibr" rid="ref-883776861">[39]</xref>
          <xref ref-type="bibr" rid="ref-1377238325">[40]</xref>
          <xref ref-type="bibr" rid="ref-1828640626">[41]</xref>
          <xref ref-type="bibr" rid="ref-3029952268">[42]</xref>, patients with ILI present to care more frequently in France, but probably their symptoms are less severe than in New Zealand. Thus the probability of hospitalization given presentation to care with ILI is lower in France than in New Zealand <xref ref-type="bibr" rid="ref-883776861">[39]</xref>
          <xref ref-type="bibr" rid="ref-1377238325">[40]</xref>
          <xref ref-type="bibr" rid="ref-1828640626">[41]</xref>
          <xref ref-type="bibr" rid="ref-3029952268">[42]</xref>. In the second two-way sensitivity analysis, we varied oseltamivir efficacy and the probability of A(H1N1)<italic>v</italic> influenza given presentation to care with ILI across broad ranges, In these two-way sensitivity analyses we generally considered scenarios that reduced the benefits of the systematic strategy. 
        </p></sec><sec id="sec7"><title>Software</title><!--WRITE-PARA--><p id="p15">The model was built with TreeAge ProTM 2006 software (Williamstown, MA,USA).&#x02028;
        </p></sec></sec><sec id="sec8"><title>
        <bold>Results</bold>
      </title><sec id="sec9"><title>Base-case analysis (Table 2)</title><!--WRITE-PARA--><p id="p17">When the targeted strategy was implemented over the course of an 11-week A(H1N1)<italic>v</italic> influenza epidemic, 14,460 patients were hospitalized, 1,696 were admitted to the ICU, and 238 died. In the systematic strategy, 12,339 patients were hospitalized, 1,447 were admitted to the ICU, and 203 died. Compared to the targeted strategy, the systematic strategy thus reduced hospitalizations by 2,121, ICU admissions by 249, and deaths by 35. Overall direct medical costs were &#x020ac;86,237,980 in the targeted strategy and &#x020ac;89,591,030 in the systematic strategy. The systematic strategy increased life expectancy by 817 discounted life years for an additional cost of &#x020ac;3,353,050 compared to the targeted strategy, leading to a cost-effectiveness ratio of &#x020ac;4,100/YLG.</p></sec><sec id="sec10"><title>Sensitivity analyses (Table 3)</title><!--WRITE-PARA--><p id="p18">In univariate sensitivity analysis, results were most sensitive to variations in the probability of A(H1N1)<italic>v</italic> influenza given presentation to care with ILI, the probability of hospitalization given diagnosis with A(H1N1)<italic>v</italic> influenza, and oseltamivir efficacy. When we reduced the probability of diagnosing A(H1N1)<italic>v</italic> influenza in patients who present to care with ILI from 21.5% to 5%, systematic treatment reduced deaths by eight and led to a cost-effectiveness ratio of &#x020ac;49,300/YLG compared to the targeted strategy. When we decreased the probability of hospitalization from 5.5% to 1.37% in patients with A(H1N1)<italic>v</italic> influenza, systematic treatment reduced deaths by eight and produced a cost-effectiveness ratio of &#x020ac;45,500/YLG compared to the targeted strategy. When oseltamivir reduced the probability of hospitalization by 5% rather than 60% in the base case, the systematic strategy reduced deaths by three and was associated with a cost-effectiveness ratio of &#x020ac;155,200/YLG.</p><!--WRITE-PARA--><p id="p19">Variations in the epidemic attack rate had an impact on overall deaths and costs, but not on cost-effectiveness. When we increased the attack rate from 7.5% to 20%, reductions in mortality produced by systematic treatment increased from 35 to 93. Overall costs increased from &#x020ac;3,353,050 to &#x020ac;8,941,480. </p><!--WRITE-PARA--><p id="p20">Increases in the probability of presentation to care with ILI among low-risk patients had an impact on cost-effectiveness in univariate sensitivity analysis. When we doubled the proportion of low-risk patients who presented to care in the systematic strategy and assumed that 50% of them received antiviral treatment, the cost-effectiveness of systematic treatment compared to targeted treatment was &#x020ac;40,000/YLG. Cost-effectiveness ratios remained stable when we increased the probability of presentation to care with ILI in both low- and high-risk patients. When we simultaneously increased presentation to care with ILI and decreased hospitalizations, cost-effectiveness ratios increased. For example, when we increased the probability of presentation to care to 30% and decreased the probability of hospitalization to 1%, the systematic strategy led to a cost-effectiveness ratio of &#x020ac;65,900/YLG compared to the targeted strategy.</p><!--WRITE-PARA--><p id="p21">In a second two-way sensitivity analysis, we varied both oseltamivir efficacy and the probability of diagnosing A(H1N1)<italic>v</italic> influenza in patients who present to care with ILI (Figure 2). Under the conservative assumption that antiviral treatment reduces the probability of hospitalization by 10% and that 15% of patients with ILI are A(H1N1)<italic>v</italic>-infected, the cost-effectiveness of systematic treatment compared to targeted treatment increased to &#x020ac;108,200/YLG. When we further reduced the proportion of A(H1N1)<italic>v</italic>-infected patients to 10% and 5%, the systematic strategy led to cost-effectiveness ratios of &#x020ac;167,200/YLG and &#x020ac;344,000/YLG compared to the targeted strategy. </p></sec></sec><sec id="sec11"><title>
        <bold>Discussion</bold>
      </title><!--WRITE-PARA--><p id="p23">We used available data on the A(H1N1)<italic>v</italic> influenza epidemic in New Zealand to build a decision model and assess the clinical benefits and cost-effectiveness of different antiviral treatment strategies in the French population. Systematic initiation of neuraminidase inhibitors in patients who present to care with ILI during an A(H1N1)<italic>v</italic> influenza epidemic wave reduces mortality compared to a strategy that only targets patients at high risk of developing complications, and leads to a cost-effectiveness ratio of &#x020ac;4,100/YLG. According to the World Health Organization Commission on Macroeconomics and Health, an intervention is cost-effective if it delivers life years at a cost below three times the per capita Gross Domestic Product (GDP) (&#x020ac;91,240 for France in 2008) <xref ref-type="bibr" rid="ref-2309517909">[43]</xref>. The systematic strategy falls well below this threshold. Clinical benefits and cost-effectiveness were sensitive to the probability of A(H1N1)<italic>v</italic> influenza in patients who present to care with ILI, the probability of hospitalization among A(H1N1)<italic>v</italic>-infected patients and, most importantly, oseltamivir efficacy. Clinical benefits were also sensitive to variations in the A(H1N1)<italic>v </italic>influenza attack rate and the probability of ICU admission given hospitalization. </p><!--WRITE-PARA--><p id="p24">To assess the internal validity of the model, we compared the model-based incidence of ICU admissions to the incidence of ICU admissions recently reported in Australia and New Zealand. The model projected 26.4 admissions per million people, compared to 28.7 (95% confidence interval [CI], 26.5-30) in Australia and New Zealand <xref ref-type="bibr" rid="ref-3758611592">[44]</xref>. Model projections were within 10% and almost within the 95% CI of reported ICU admissions.</p><!--WRITE-PARA--><p id="p25">To our knowledge, the cost-effectiveness of antiviral treatment against A(H1N1)<italic>v</italic> influenza has never been evaluated, although several studies have investigated the impact of treating patients with seasonal human influenza <xref ref-type="bibr" rid="ref-429906310">[29]</xref>
        <xref ref-type="bibr" rid="ref-268547865">[45]</xref>
        <xref ref-type="bibr" rid="ref-3057083638">[46]</xref>
        <xref ref-type="bibr" rid="ref-4255889922">[47]</xref>
        <xref ref-type="bibr" rid="ref-2662844829">[48]</xref>. The cost-effectiveness of antiviral treatment in these studies varies widely <xref ref-type="bibr" rid="ref-1061940129">[49]</xref>, particularly when treatment is compared to supportive care. These differences are mainly due to variations in study perspective, cohort characteristics, and other model parameters. Although study results should be compared with caution, it should be noted that the cost-effectiveness of systematic treatment in our study is lower than in previous studies, despite the absence of quality of life considerations in our analysis. In a recent study on seasonal human influenza, the probability that patients who presented to care with ILI had influenza was 46% and the probability of presentation to care &#x0003c;48 hours after the onset of symptoms was 20%. The authors found that oseltamivir treatment in low-risk persons aged 12-65 years was associated with a cost-effectiveness ratio of &#x000a3;32,400 per quality-adjusted life year saved (QALY; 2009 &#x020ac;36,600/QALY) compared to no treatment <xref ref-type="bibr" rid="ref-429906310">[29]</xref>. The cost-effectiveness ratios reported in these studies are higher than in our study, most likely because the hospitalization and mortality rates associated with seasonal influenza among young and low-risk populations are lower than for A(H1N1)<italic>v</italic> influenza <xref ref-type="bibr" rid="ref-4114420138">[14]</xref>
        <xref ref-type="bibr" rid="ref-150613430">[15]</xref>
        <xref ref-type="bibr" rid="ref-3809112805">[16]</xref>
        <xref ref-type="bibr" rid="ref-669132870">[17]</xref>
        <xref ref-type="bibr" rid="ref-1521450404">[18]</xref>. The severity of the current A(H1N1)<italic>v </italic>pandemic is uncertain because data on prevalence and hospitalization rates are imperfect. We addressed this issue by using data from New Zealand, where the influenza season is nearly over, and by performing a wide range of sensitivity analyses, particularly on the probability of hospitalization among patients who present to care with A(H1N1)<italic>v</italic> influenza, as reported by Presanis <italic>et al</italic>. in the United States <xref ref-type="bibr" rid="ref-669132870">[17]</xref>. Systematic treatment with neuraminidase inhibitors in patients who present to care with ILI remained effective and cost-effective in sensitivity analysis.
      </p><!--WRITE-PARA--><p id="p26">Variations in antiviral treatment efficacy had a large impact on results. When we decreased the efficacy of oseltamivir, the clinical benefits of systematic treatment decreased and cost-effectiveness ratios increased. A recent systematic review and meta-analysis has suggested that, even for seasonal human influenza, data are insufficient to draw conclusions on the impact of neuraminidase inhibitors on complication rates in low- and high-risk populations <xref ref-type="bibr" rid="ref-1863690772">[50]</xref>. Our estimate of oseltamivir efficacy is from Kaiser <italic>et al</italic>.&#x02019;s meta-analysis of 10 placebo-controlled double-blind trials of oseltamivir treatment, which enrolled a total of 3,564 subjects with ILI. This meta-analysis found however very few events in both low- and high-risk populations <xref ref-type="bibr" rid="ref-3555451527">[28]</xref>. A study conducted with data from Thailand&#x02019;s National Avian Influenza Surveillance (NAIS) system showed that survival after treatment with oseltamivir was associated with a crude odds ratio of 0.11 (95% CI, 0.04-0.30) <xref ref-type="bibr" rid="ref-1307388359">[51]</xref>. This estimate is higher than ours, but it was derived from a retrospective observational study and should therefore be considered with caution. A recent study performed in the United States suggests that all patients with A(H1N1)<italic>v</italic> influenza benefit from antiviral treatment, regardless of risk status. Among patients who were hospitalized, were not admitted to the ICU, and survived, 45% initiated antiviral treatment &#x0003c;48 hours after the onset of symptoms. Among patients who were hospitalized, were admitted to the ICU, and died, only 23% initiated antiviral therapy early <xref ref-type="bibr" rid="ref-3491413473">[19]</xref>. These data are consistent with our hypothesis on antiviral treatment efficacy. However, we varied oseltamivir efficacy over a wide range in sensitivity analysis. When oseltamivir reduced hospitalization rates by &#x0003c;8%, the clinical benefits of systematic treatment were low and the cost-effectiveness ratio increased to above the WHO threshold for cost-effectiveness <xref ref-type="bibr" rid="ref-2309517909">[43]</xref>.</p><!--WRITE-PARA--><p id="p27">Results were sensitive to the probability of diagnosing A(H1N1)<italic>v</italic> influenza in patients with ILI. When this probability decreased, the systematic strategy became less effective and less cost-effective. When we set it to 5% and decreased oseltamivir efficacy, clinical benefits were small and cost-effectiveness ratios increased sharply. Given uncertainties surrounding the efficacy of neuraminidase inhibitors, and in the absence of rapid A(H1N1)<italic>v</italic> diagnostic tests that might reduce inappropriate neuraminidase inhibitor use, physicians should initiate antiviral treatment in all patients with ILI when A(H1N1)<italic>v</italic> reaches epidemic rates, but not between epidemic waves.</p><!--WRITE-PARA--><p id="p28">Mortality rates were especially sensitive to the A(H1N1)<italic>v</italic> influenza attack rate. When we increased the attack rate, mortality differences between the systematic strategy and the targeted strategy increased, but cost-effectiveness ratios remained stable. The attack rate in our analysis, derived from New Zealand data, is lower than predictions for upcoming A(H1N1)<italic>v</italic> epidemics. If A(H1N1)<italic>v</italic> influenza attack rates increase, the systematic strategy will be much more effective and cost-effectiveness ratios will remain stable. </p><!--WRITE-PARA--><p id="p29">This study has several limitations. First, our model combines input data from several sources and relies on several assumptions to estimate the impact of different antiviral treatment strategies. In particular, we used data from New Zealand on the probabilities of presenting to care with ILI, A(H1N1)<italic>v</italic> influenza given presentation to care with ILI, hospitalization given A(H1N1)<italic>v</italic>, ICU admission given hospitalization, and death given ICU admission <xref ref-type="bibr" rid="ref-3335166991">[27]</xref>. Although prevention and control measures, and recommendations for A(H1N1)<italic>v</italic> pandemic influenza management and antiviral treatment use in New Zealand are similar in many other developed countries <xref ref-type="bibr" rid="ref-2676606313">[9]</xref>
        <xref ref-type="bibr" rid="ref-3062049286">[10]</xref>
        <xref ref-type="bibr" rid="ref-309199049">[11]</xref>
        <xref ref-type="bibr" rid="ref-1623490564">[12]</xref>, the characteristics of the epidemic and healthcare resource utilization may be different in other settings. However, our results remained stable when we used more conservative estimates for the probabilities of presentation to care with ILI and hospitalization given ILI. Second, the impact of neuraminidase inhibitors on complication rates is uncertain. Our results were robust to variations in treatment efficacy, except when the probability of diagnosing A(H1N1)<italic>v</italic> influenza in patients with ILI was low. Third, we did not account for oseltamivir-related adverse events, but these events are rare and it is unlikely that they would impact our results. Fourth, we did not account for resistance to oseltamivir, which could become more frequent as the availability of neuraminidase inhibitors increases. However, resistance generally emerges in patients who take antiviral drugs as pre- or post-exposure prophylaxis, or because of severe immunosuppression <xref ref-type="bibr" rid="ref-3285149995">[52]</xref>
        <xref ref-type="bibr" rid="ref-3661812639">[53]</xref>
        <xref ref-type="bibr" rid="ref-1999133293">[54]</xref>. Fifth, we did not consider the impact of A(H1N1)<italic>v</italic> influenza on quality of life or productivity and the impact of antiviral treatment on influenza transmission. In addition, we did not incorporate the economic benefits of stockpiling oseltamivir in preparation for an eventual influenza pandemic, as has been done in France and other countries. Because antiviral treatment is already in stock, medical costs in France will be lower than those used in our study. The systematic strategy is even more cost-effective if we take these parameters into account. Finally, we did not consider the effects of A(H1N1)<italic>v</italic> influenza vaccination. The results of our study cannot be extrapolated to a vaccinated population because the severity of disease in vaccinated and unvaccinated populations may differ. However, it is likely that a large proportion of the general population in France will refuse to be vaccinated <xref ref-type="bibr" rid="ref-3196184313">[55]</xref>, and most countries have recommended vaccination for high-risk groups only <xref ref-type="bibr" rid="ref-4292333614">[56]</xref>
        <xref ref-type="bibr" rid="ref-2017487156">[57]</xref>. &#x02028;
      </p><!--WRITE-PARA--><p id="p30">Guidelines for antiviral treatment use in patients with A(H1N1)<italic>v</italic> influenza are currently based on our understanding of seasonal human influenza. However, the proportion of healthy young people with A(H1N1)<italic>v</italic> influenza who develop severe or fatal complications is higher than for seasonal human influenza. As demonstrated in this analysis, systematic treatment of all patients with ILI during an A(H1N1)<italic>v </italic>influenza epidemic wave is both effective and cost-effective. Additional data on the efficacy of neuraminidase inhibitors in preventing influenza complications should be collected to improve clinical and cost-effectiveness estimates. Meanwhile, all patients who present to care with ILI during an A(H1N1 influenza epidemic wave should initiate treatment with neuraminidase inhibitors. Decision makers and clinicians should use caution when administering neuraminidase inhibitors between epidemic waves, when the probability of influenza is low.</p></sec><sec id="sec12"><title>
        <bold>Tables and Figures</bold>
      </title><sec id="sec13"><title>
          <bold>Table 1. Summary of input parameters for </bold>
          <bold>a decision model of A(H1N1)<italic>v</italic> influenza treatment</bold>
        </title><!--WRITE-PARA--><p id="p31">
          <table-wrap id="d20e745"><table border="0" cellpadding="0" cellspacing="0"><tbody><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:329.4pt">
                    <bold>Variable</bold>
                  </td><td valign="top" rowspan="1" colspan="1" style="width:66pt">
                    <bold>Baseline value</bold>
                  </td><td valign="top" rowspan="1" colspan="1" style="width:48pt">
                    <bold>Range</bold>
                  </td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <bold>Source</bold>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">
                    Cohort characteristics 
                  <break/>Mean age, years<break/>Life expectancy, years<break/>Proportion of patients at high risk of complications, %<sup>*</sup></td><td valign="top" rowspan="1" colspan="1" style="width:66pt">64,300,000<break/>40<break/>41<break/>23</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">-<break/>20<break/>60<break/>23-40</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <xref ref-type="bibr" rid="ref-1898167246">[25]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td colspan="4" valign="top" rowspan="1" style="width:514.2pt">
                    A(H1N1)<italic>v</italic> epidemic characteristics in the targeted strategy 
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">Attack rate, %</td><td valign="top" rowspan="1" colspan="1" style="width:66pt">7.5</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">7.5-15.0</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <xref ref-type="bibr" rid="ref-3335166991">[27]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">Probability of ILI, %<sup>&#x02020;</sup></td><td valign="top" rowspan="1" colspan="1" style="width:66pt">34.9</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">34.9-69.8</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <xref ref-type="bibr" rid="ref-3335166991">[27]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">Probability of presenting to care with ILI, %<sup>&#x02021;</sup></td><td valign="top" rowspan="1" colspan="1" style="width:66pt">5.5</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">5.5-30.0</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <xref ref-type="bibr" rid="ref-3335166991">[27]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">Probability of A(H1N1)<italic>v</italic> given presentation to care with ILI, %<sup>&#x000a7;</sup></td><td valign="top" rowspan="1" colspan="1" style="width:66pt">21.5</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">5.0-15.0</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <xref ref-type="bibr" rid="ref-3335166991">[27]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">Probability of hospitalization given presentation to care with ILI and A(H1N1)<italic>v</italic>, %<sup>&#x02551;</sup></td><td valign="top" rowspan="1" colspan="1" style="width:66pt">5.5</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">1.4-5.5</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <xref ref-type="bibr" rid="ref-669132870">[17]</xref>
                    <xref ref-type="bibr" rid="ref-3335166991">[27]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">Increased hospitalizations in high-risk patients <italic>vs.</italic> low-risk patients <sup>&#x000b6;</sup></td><td valign="top" rowspan="1" colspan="1" style="width:66pt">2.7</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">-</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <xref ref-type="bibr" rid="ref-150613430">[15]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">Probability of ICU admission given hospitalization, %<sup>**</sup></td><td valign="top" rowspan="1" colspan="1" style="width:66pt">12</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">6-24</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <xref ref-type="bibr" rid="ref-3335166991">[27]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">Increased ICU admissions in high-risk patients <italic>vs.</italic> low-risk patients</td><td valign="top" rowspan="1" colspan="1" style="width:66pt">1.0</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">1.0-3.0</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <xref ref-type="bibr" rid="ref-3335166991">[27]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">Probability of death given ICU admission, %<sup>**</sup></td><td valign="top" rowspan="1" colspan="1" style="width:66pt">14</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">-</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <xref ref-type="bibr" rid="ref-3335166991">[27]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td colspan="4" valign="top" rowspan="1" style="width:514.2pt">
                    Antiviral treatment use and efficacy in the systematic strategy
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">Proportion of patients who present to care and initiate treatment &#x0003c;48 hours after the onset of symptoms, %<sup>&#x02020;&#x02020;</sup></td><td valign="top" rowspan="1" colspan="1" style="width:66pt">50</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">25-75</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <xref ref-type="bibr" rid="ref-150613430">[15]</xref>
                    <xref ref-type="bibr" rid="ref-429906310">[29]</xref>
                    <xref ref-type="bibr" rid="ref-479242327">[30]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">Proportion of patients who initiate treatment &#x0003e;48 hours after the onset of symptoms, %</td><td valign="top" rowspan="1" colspan="1" style="width:66pt">6.1</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">3.1-9.2</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <xref ref-type="bibr" rid="ref-150613430">[15]</xref>
                    <xref ref-type="bibr" rid="ref-429906310">[29]</xref>
                    <xref ref-type="bibr" rid="ref-479242327">[30]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">Antiviral treatment efficacy, %</td><td valign="top" rowspan="1" colspan="1" style="width:66pt">60</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">5-30</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <xref ref-type="bibr" rid="ref-3555451527">[28]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">
                    Health care resource utilization and costs
                  </td><td valign="top" rowspan="1" colspan="1" style="width:66pt">
                    <bold>&#x000a0;</bold>
                  </td><td valign="top" rowspan="1" colspan="1" style="width:48pt">
                    <bold>&#x000a0;</bold>
                  </td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <bold>&#x000a0;</bold>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">Clinic visit</td><td valign="top" rowspan="1" colspan="1" style="width:66pt">21</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">-</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">&#x000a0;</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">Average length of inpatient stay, days</td><td valign="top" rowspan="1" colspan="1" style="width:66pt">4</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">7</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <xref ref-type="bibr" rid="ref-668597037">[38]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">Average length of ICU admission, days</td><td valign="top" rowspan="1" colspan="1" style="width:66pt">13</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">21</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <xref ref-type="bibr" rid="ref-668597037">[38]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">Cost per inpatient day, 2009 &#x020ac;</td><td valign="top" rowspan="1" colspan="1" style="width:66pt">482&#x020ac;</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">-</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <xref ref-type="bibr" rid="ref-415459089">[35]</xref>
                    <xref ref-type="bibr" rid="ref-1046517456">[36]</xref>
                    <xref ref-type="bibr" rid="ref-1657402311">[37]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">Cost per ICU day, 2009 &#x020ac;</td><td valign="top" rowspan="1" colspan="1" style="width:66pt">1,319&#x020ac;</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">-</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">
                    <xref ref-type="bibr" rid="ref-415459089">[35]</xref>
                    <xref ref-type="bibr" rid="ref-1046517456">[36]</xref>
                    <xref ref-type="bibr" rid="ref-1657402311">[37]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="font-family:arial,sans-serif;width:329.4pt">5-day oseltamivir treatment by age, 2009 &#x020ac;<break/>&#x0003c;1 year<break/>1-12 years<break/>&#x0003e;12 years</td><td valign="top" rowspan="1" colspan="1" style="width:66pt">&#x000a0;<break/>12.69 <break/>18.78<break/>24.85</td><td valign="top" rowspan="1" colspan="1" style="width:48pt">&#x000a0;<break/>-<break/>-<break/>-</td><td valign="top" rowspan="1" colspan="1" style="width:70.8pt">&#x000a0;<break/>
                    <xref ref-type="bibr" rid="ref-539055477">[32]</xref>
                  </td></tr><tr style="font-family:arial,sans-serif"><td colspan="4" valign="top" rowspan="1" style="width:514.2pt">ILI: influenza-like illness; ICU: intensive care unit<break/>
                    <sup>*</sup>Patients at high risk of complications include patients aged &#x0003e;65 years; infants aged &#x0003c;1 year; pregnant women; and patients with chronic respiratory diseases, chronic cardiovascular diseases, diabetes, obesity and immunosuppression. 
                  <break/>
                    <sup>&#x02020;</sup>The probability of ILI is 0.019062 x 18.3, from Baker <italic>at al</italic>. <xref ref-type="bibr" rid="ref-3335166991">[27]</xref>. In this study, only one in 18.3 patients with ILI presented to care and the cumulative rate of presentation to care with ILI during an epidemic wave was 1.9062%. 
                  <break/>
                    <sup>&#x02021;</sup>The probability of presenting to care with ILI is 1/18.3, from Baker <italic>et al</italic>. <xref ref-type="bibr" rid="ref-3335166991">[27]</xref>. 
                  <break/>
                    <sup>&#x000a7;</sup>The probability of A(H1N1)<italic>v</italic> given presentation to care with ILI is 408.9/1906.2, from Baker <italic>et al</italic>. <xref ref-type="bibr" rid="ref-3335166991">[27]</xref>. In this sudy, the cumulative rate of A(H1N1)<italic>v</italic> diagnosis among patients presenting to care with ILI during an epidemic wave was 408.9/100,000. 
                  <break/>
                    <sup>&#x02551;</sup>The probability of hospitalization given presentation to care with ILI and A(H1N1)<italic>v</italic> diagnosis is 972/17672, from Baker <italic>et al</italic>. <xref ref-type="bibr" rid="ref-3335166991">[27]</xref>. 
                  <break/>
                    <sup>&#x000b6;</sup>The difference in hospitalization rates between low- and high-risk patients is (20/108)/(220/3162), from Gilsdorf <italic>et al</italic>. <xref ref-type="bibr" rid="ref-150613430">[15]</xref>. In this study, the hospitalization rate was 20/108 in high-risk patients and 220/3162 in low-risk patients. 
                  <break/>
                    <sup>**</sup>The probability of ICU admission given hospitalization is from Baker <italic>et al</italic>. <xref ref-type="bibr" rid="ref-3335166991">[27]</xref>. In this study, 114/972 hospitalized patients were admitted to the ICU, and 16/114 ICU admissions died. 
                  <break/>
                    <sup>&#x02020;&#x02020;</sup>Based on the physician&#x02019;s deduction. 
                  </td></tr></tbody></table></table-wrap>
        </p></sec><sec id="sec14"><title>
          <bold>Table 2. Base case results for different antiviral treatment strategies in France</bold>
        </title><!--WRITE-PARA--><p id="p146">
          <table-wrap id="d20e1316"><table border="0" cellpadding="0" cellspacing="0"><tbody><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">&#x000a0;</td><td colspan="2" valign="top" rowspan="1" style="width:1.5in">
                    <bold>Hospitalizations</bold>
                  </td><td rowspan="2" valign="top" colspan="1" style="width:0.75in">
                    <bold>Deaths</bold>
                  </td><td rowspan="2" valign="top" colspan="1" style="width:91.5pt">
                    <bold>Discounted life years</bold>
                  </td><td rowspan="2" valign="top" colspan="1" style="width:80.4pt">
                    <bold>Undiscountedcosts (&#x020ac;)<sup>*</sup></bold>
                  </td><td rowspan="2" valign="top" colspan="1" style="width:60pt">
                    <bold>CER (&#x020ac;/LYG)</bold>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:0.75in">
                    <bold>Overall</bold>
                  </td><td valign="top" rowspan="1" colspan="1" style="width:0.75in">
                    <bold>ICU</bold>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">Targeted strategy<sup>&#x02020;</sup></td><td valign="top" rowspan="1" colspan="1" style="width:0.75in">14,460</td><td valign="top" rowspan="1" colspan="1" style="width:0.75in">1,696</td><td valign="top" rowspan="1" colspan="1" style="width:0.75in">238</td><td valign="top" rowspan="1" colspan="1" style="width:91.5pt">5,573</td><td valign="top" rowspan="1" colspan="1" style="width:80.4pt">86,237,980</td><td valign="top" rowspan="1" colspan="1" style="width:60pt">&#x000a0;</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">Systematic strategy<sup>&#x02021;</sup></td><td valign="top" rowspan="1" colspan="1" style="width:0.75in">12,339</td><td valign="top" rowspan="1" colspan="1" style="width:0.75in">1,447</td><td valign="top" rowspan="1" colspan="1" style="width:0.75in">203</td><td valign="top" rowspan="1" colspan="1" style="width:91.5pt">4,755</td><td valign="top" rowspan="1" colspan="1" style="width:80.4pt">89,591,030</td><td valign="top" rowspan="1" colspan="1" style="width:60pt">4,100</td></tr><tr><td colspan="7" valign="top" rowspan="1" style="width:507.3pt">ICU: intensive care unit; CER: cost-effectiveness ratio; LYG: life years gained<break/>
                    <sup>*</sup>Costs were not discounted, because all costs were incurred within 1 year of presentation to care.
                  <break/>
                    <sup>&#x02020;</sup>Early treatment with neuraminidase inhibitors in patients who present to care with ILI and are at high risk of complications, as currently recommended in France.
                  <break/>
                    <sup>&#x02021;</sup>Early treatment with neuraminidase inhibitors in all patients who present to care with ILI.
                  </td></tr></tbody></table></table-wrap>
          &#x02028;
        </p></sec><sec id="sec16"><title>
          <bold>Table 3. Sensitivity analyses</bold>
        </title><!--WRITE-PARA--><p id="p174">
          <table-wrap id="d20e1453"><table border="0" cellpadding="0" cellspacing="0"><tbody><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">
                    <bold>&#x000a0;</bold>
                  </td><td colspan="3" valign="top" rowspan="1" style="width:260pt">
                    <bold>Targeted strategy</bold>
                  </td><td colspan="3" valign="top" rowspan="1" style="width:258pt">
                    <bold>Systematic strategy</bold>
                  </td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">
                    <bold>CER</bold>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">
                    <bold>&#x000a0;</bold>
                  </td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">
                    <bold>Deaths</bold>
                  </td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">
                    <bold>Discounted life years</bold>
                  </td><td valign="top" rowspan="1" colspan="1" style="width:80pt">
                    <bold>Cost (&#x020ac;)<sup>*</sup></bold>
                  </td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">
                    <bold>Deaths</bold>
                  </td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">
                    <bold>Discounted life years</bold>
                  </td><td valign="top" rowspan="1" colspan="1" style="width:80pt">
                    <bold>Cost (&#x020ac;)<sup>*</sup></bold>
                  </td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">
                    <bold>&#x020ac;/LYG</bold>
                  </td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">Base-case</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">5,573</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">86,237,980</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">203</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">4,755</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">89,591,030</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">4,100</td></tr><tr style="font-family:arial,sans-serif"><td colspan="3" valign="top" rowspan="1" style="width:293.4pt">Mean age (base case: 40 years)</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">&#x000a0;</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">20 years</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">6,587</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">86,237,980</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">203</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">5,521</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">89,591,030</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">2,500</td></tr><tr style="font-family:arial,sans-serif"><td colspan="4" valign="top" rowspan="1" style="width:373.4pt">Percent of patients at high risk of complication (base case: 23%)</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">
                    &#x02028;
                  </td><td valign="top" rowspan="1" colspan="1" style="width:80pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">&#x000a0;</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">30%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">5,573</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">88,311,420</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">209</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">4,887</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">91,915,250</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">5,300</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">40%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">5,573</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">91,973,470</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">215</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">5,044</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">94,927,350</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">6,900</td></tr><tr style="font-family:arial,sans-serif"><td colspan="3" valign="top" rowspan="1" style="width:293.4pt">Attack rate (base case: 7.5%)</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">&#x000a0;</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">15%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">476</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">11,145</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">172,475,960</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">406</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">9,511</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">179,182,060</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">4,100</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">20%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">635</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">14,860</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">229,967,940</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">542</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">12,680</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">238,909,420</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">4,100</td></tr><tr style="font-family:arial,sans-serif"><td colspan="4" valign="top" rowspan="1" style="width:373.4pt">Probability of presenting to care with ILI (base case: 5.5%)</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">&#x000a0;</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">10%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">436</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">10,198</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">157,815,500</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">372</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">8,702</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">163,951,590</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">4,100</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">20%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">871</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">20,396</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">315,631,000</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">743</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">17,405</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">327,903,180</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">4,100</td></tr><tr style="font-family:arial,sans-serif"><td colspan="6" valign="top" rowspan="1" style="width:551.4pt">Probability of A(H1N1)<italic>v</italic> influenza given presentation to care with ILI (base case: 21.5%)</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">&#x000a0;</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">15%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">166</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">3,897</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">70,092,030</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">142</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">3,325</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">75,812,970</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">10,000</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">10%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">111</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">2,598</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">57,577,840</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">95</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">2,217</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">65,134,040</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">19,800</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">5%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">55</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">1,299</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">45,063,640</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">47</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">1,108</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">54,455,120</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">49,300</td></tr><tr style="font-family:arial,sans-serif"><td colspan="8" valign="top" rowspan="1" style="width:705.65pt">Probability of hospitalization given presentation to care with ILI and A(H1N1)<italic>v</italic> (base case: 5.5%)</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">1.37%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">59</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">1,388</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">45,922,220</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">51</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">1,184</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">55,187,790</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">45,500</td></tr><tr style="font-family:arial,sans-serif"><td colspan="8" valign="top" rowspan="1" style="width:705.65pt">Probability of presenting to care with ILI (base case: 5.5%) and probability of hospitalization given presentation to care with ILI and A(H1N1)<italic>v</italic> (base case: 5.5%)</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">10% and 3.0%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">5,562</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">113,154,200</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">203</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">4,747</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">125,840,090</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">15,600</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">20% and 1.5%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">5,562</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">172,719,690</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">203</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">4,747</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">205,950,530</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">40,700</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">30% and 1.0%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">5,562</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">232,285,170</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">203</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">4,747</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">286,060,970</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">65,900</td></tr><tr style="font-family:arial,sans-serif"><td colspan="4" valign="top" rowspan="1" style="width:373.4pt">Probability of ICU admission given hospitalization (base case: 12%)</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">&#x000a0;</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">6%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">122</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">2,851</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">73,631,840</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">104</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">2,433</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">78,833,650</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">12,400</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">24%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">487</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">11,403</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">113,243,380</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">416</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">9,731</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">112,635,950</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">Cost-saving</td></tr><tr style="font-family:arial,sans-serif"><td colspan="4" valign="top" rowspan="1" style="width:373.4pt">Increased ICU admissions in high-risk <italic>vs</italic>. low-risk patients (base case: 1)</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">&#x000a0;</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">&#x000cd;2</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">279</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">6,537</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">90,705,530</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">251</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">5,873</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">94,766,380</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">6,100</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">&#x000cd;3</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">307</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">7,198</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">93,765,500</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">284</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">6,638</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">98,311,140</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">8,100</td></tr><tr style="font-family:arial,sans-serif"><td colspan="6" valign="top" rowspan="1" style="width:551.4pt">Proportion of patients who present to care &#x02264;48 hours after the onset of symptoms (base case: 50%)<sup>&#x02021;</sup></td><td valign="top" rowspan="1" colspan="1" style="width:80pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">&#x000a0;</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">25%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">5,573</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">86,237,980</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">221</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">5,164</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">87,914,510</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">4,100</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">75%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">5,573</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">86,237,980</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">186</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">4,347</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">91,267,560</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">4,100</td></tr><tr style="font-family:arial,sans-serif"><td colspan="8" valign="top" rowspan="1" style="width:705.65pt">Proportion of new patients treated when proportion of low-risk patients presenting to care with ILI is doubled (base case: 5.5%)<sup>&#x02020;</sup></td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">0</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">5,573</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">86,237,980</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">203</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">4,755</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">108,325,390</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">27,000</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">50% </td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">5,573</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">86,237,980</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">203</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">4,755</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">118,938,660</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">40,000</td></tr><tr style="font-family:arial,sans-serif"><td colspan="5" valign="top" rowspan="1" style="width:430.5pt">Antiviral treatment efficacy (base case: 60% reduction in hospitalization rate)</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">&#x000a0;</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">30%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">5,573</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">86,237,980</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">221</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">5,164</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">93,527,880</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">17,800</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">15%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">5,573</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">86,237,980</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">229</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">5,368</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">95,496,300</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">45,300</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">5%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">5,573</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">86,237,980</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">235</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">5,505</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">96,808,590</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">155,200</td></tr><tr style="font-family:arial,sans-serif"><td colspan="3" valign="top" rowspan="1" style="width:293.4pt">Average length of inpatient stay (base case: 4 days)</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">&#x000a0;</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">7 days</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">5,573</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">104,694,610</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">203</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">4,755</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">105,340,900</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">800</td></tr><tr style="font-family:arial,sans-serif"><td colspan="3" valign="top" rowspan="1" style="width:293.4pt">Average length of ICU admission (base case: 13 days)</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">&#x000a0;</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">21 days</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">5,573</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">104,133,170</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">203</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">4,755</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">104,861,910</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">900</td></tr><tr style="font-family:arial,sans-serif"><td colspan="3" valign="top" rowspan="1" style="width:293.4pt">Discount rate (base case: 3%)</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">&#x000a0;</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">0%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">9,759</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">86,237,980</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">203</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">8,328</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">89,591,030</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">2,300</td></tr><tr style="font-family:arial,sans-serif"><td valign="top" rowspan="1" colspan="1" style="width:113.4pt">5%</td><td valign="top" rowspan="1" colspan="1" style="width:57.2pt">238</td><td valign="top" rowspan="1" colspan="1" style="width:122.8pt">4,116</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">86,237,980</td><td valign="top" rowspan="1" colspan="1" style="width:57.1pt">203</td><td valign="top" rowspan="1" colspan="1" style="width:120.9pt">3,513</td><td valign="top" rowspan="1" colspan="1" style="width:80pt">89,591,030</td><td valign="top" rowspan="1" colspan="1" style="width:74.25pt">5,600</td></tr><tr><td colspan="8" valign="top" rowspan="1" style="width:705.65pt">ICU: intensive care unit; CER: cost-effectiveness ratio; LYG: life years gained<break/>
                    <sup>*</sup>Costs were not discounted, because all costs were incurred within 1 year of presentation to care.
                  <break/>
                    <sup>&#x02020;</sup>We only varied this probability in low-risk patients in the systematic strategy, to test the hypothesis that universal antiviral use might encourage these patients to seek care.
                  <break/>
                    <sup>&#x02021;</sup>We assumed that 49% of patients who initiated treatment on the second day of symptoms did not recall the onset of their symptoms accurately, and that half of them presented to care &#x0003e;48 hours after the onset of symptoms <xref ref-type="bibr" rid="ref-429906310">[29]</xref>
                    <xref ref-type="bibr" rid="ref-479242327">[30]</xref>. In sensitivity analysis, the proportion of patients who presented to care and initiated treatment &#x0003c;48 hours after the onset of symptoms was reduced by (25% or 75%) x&#x000a0;50% x 49%.
                  </td></tr></tbody></table></table-wrap>
        </p></sec><sec id="sec17"><title>
          <bold>Figure 1&#x02028;
          </bold>
        </title><!--WRITE-PARA--><p id="p495">Decision tree. Targeted strategy: early treatment with neuraminidase inhibitors in patients who present to care with ILI and are at high risk of complications, as currently recommended in France. Systematic strategy: early treatment with neuraminidase inhibitors in all patients who present to care with ILI. Patients at high risk of complications include patients aged &#x0003e;65 years; infants aged &#x0003c;1 year; pregnant women; and patients with chronic respiratory diseases, chronic cardiovascular diseases, diabetes, obesity and immunosuppression.</p><!--WRITE-PARA--><p id="p496">
          <inline-formula><tex-math id="d20e2555">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\circ \end{equation*}\end{document}</tex-math></inline-formula> decision node&#x000a0; <inline-formula><tex-math id="d20e2560">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\diamond \end{equation*}\end{document}</tex-math></inline-formula> probability node <inline-formula><tex-math id="d20e2565">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\triangle \end{equation*}\end{document}</tex-math></inline-formula> end of one cycle
        </p></sec><sec id="sec19"><title>
          <bold>Figure 2</bold>
        </title><!--WRITE-PARA--><p id="p498">Impact of variations in antiviral treatment efficacy and the probability of A(H1N1)<italic>v</italic> influenza in patients who present to care with influenza-like illnesses on the cost-effectiveness of systematic treatment compared to targeted treatment. Antiviral efficacy was defined as the % reduction in hospitalization rates. The horizontal line represents 3 x the annual per capita gross domestic product (GDP) for France (= &#x020ac;91,240 in 2008). The World Health Organization (WHO) Commission on Macroeconomics and Health guidelines <xref ref-type="bibr" rid="ref-2309517909">[43]</xref> considers interventions below this threshold to be cost-effective. &#x02028;
          
            
            <fig id="d20e2606"><graphic xlink:href="graph"/></fig>
          
        </p></sec></sec><sec id="sec20"><title>
        <bold>Acknowledgments</bold>
      </title><!--WRITE-PARA--><p id="p499">The authors gratefully acknowledge the Institut de Microbiologie et Maladies Infectieuses for its support.</p><sec id="sec21"><title>Funding information</title><!--WRITE-PARA--><p id="p500"> This study received financial support from the Institut de Microbiologie et Maladies Infectieuses.</p></sec><sec id="sec22"><title>Competing interests
        </title><!--WRITE-PARA--><p id="p501">S. Deuffic-Burban has received grants from Roche and Janssen-Cilag. F. Carrat acts as consultant for and has received grants from Roche, GlaxoSmithKline, Sanofi-Aventis, and Novartis and has been paid to attend meetings. Y. Yazdanpanah has received travel grants, honoraria for presentation at workshops and consultancy honoraria from Bristol-Myers Squibb, Gilead, Glaxo-SmithKline, Merck, Pfizer, Roche and Tibotec. None of the other authors report any association that might pose a conflict of interest.</p></sec></sec></body><back><ref-list><ref id="ref-2928398134"><mixed-citation>World Health Organization. Pandemic (H1N1) 2009. 2009 [17 October 2009]; Available from: http://www.who.int/csr/disease/swineflu/en/.</mixed-citation></ref><ref id="ref-482322842"><mixed-citation>Pan American Heath Organization. Regional Update. Pandemic (H1N1) 2009. WHO; [updated October 9, 2009]; Available from: http://new.paho.org/hq/index.php.</mixed-citation></ref><ref id="ref-2251133444"><mixed-citation>World Health Organization (WHO) Regional Office for Europe. Pandemic (H1N1) 2009. WHO; [updated September 10, 2009]; Available from: http://www.euro.who.int/influenza/ah1n1.</mixed-citation></ref><ref id="ref-4221853969"><mixed-citation>World Health Organization (WHO) Regional Office for South-East Asia. Pandemic H1N1 2009. WHO; [updated September 27, 2009]; Available from: http://www.searo.who.int/EN/Section10/Section2562.htm.</mixed-citation></ref><ref id="ref-748790577"><mixed-citation>World Health Organization (WHO) Regional Office for the Eastern Mediterranean. Influenza A (H1N1). Latest situation in the Region. WHO; [updated October 11, 2009]; Available from: http://www.emro.who.int/csr/h1n1/.</mixed-citation></ref><ref id="ref-2310951653"><mixed-citation>World Health Organization (WHO) Regional Office for the Western Pacific. Pandemic H1N1 2009 situation. WHO; [updated August 9, 2009]; Available from: http://www.wpro.who.int/NR/rdonlyres/76F91B89-4342-4D92-83AC-526E998B5B66/0/PandemicH1N1bulletin1_WPR_Publication1_RV2.pdf.</mixed-citation></ref><ref id="ref-4290000922"><mixed-citation>World Health Organization Office for Africa. Pandemic Influenza (H1N1) 2009 - Current situation in the WHO African region. WHO; [updated October 14, 2009]; Available from: http://www.afro.who.int/.</mixed-citation></ref><ref id="ref-716910853"><mixed-citation>World Health Organization. Pandemic (H1N1) 2009 - update 68. 2009; Available from: http://www.who.int/csr/don/2009_10_02/en/index.html.</mixed-citation></ref><ref id="ref-2676606313"><mixed-citation>Centers for Disease Control and Prevention. Questions &#x00026; Answers: Antiviral Drugs, 2009-2010 Flu Season. 2009 [September 23, 2009]; Available from: http://www.cdc.gov/h1n1flu/antiviral.htm.</mixed-citation></ref><ref id="ref-3062049286"><mixed-citation>National Health Co-ordination Centre. Guidance on the diagnosis and management of Pandemic (H1N1) 2009 in the Pandemic &#x02018;Management&#x02019; phase, Version 3. 2009 [July, 30 2009]; Available from: http://www.moh.govt.nz/moh.nsf/pagesmh/9171/$File/diagnosis-and-mgmt-guidance-for-mgmt-phase-v3-30july09.doc.</mixed-citation></ref><ref id="ref-309199049"><mixed-citation>Public Health Agency of Canada. Guidance - H1N1 Flu Virus 2009; Available from: http://www.phac-aspc.gc.ca/alert-alerte/h1n1/guidance_lignesdirectrices-eng.php.</mixed-citation></ref><ref id="ref-1623490564"><mixed-citation>Minist&#x000e8;re charg&#x000e9;e de la sant&#x000e9;. Prise en charge d&#x02019;un cas de grippe A( H1N1) chez un adulte ou un enfant de plus de 40 kg. Grippe, formation, information, communication. Fiche m&#x000e9;mo; 2009; Available from: http://www.sante-sports.gouv.fr/IMG//pdf/Prise_en_charge_d_un_cas_de_grippe_A_H1N1_chez_un_adulte_ou_un_enfant_de_plus_de_40_kg.pdf.</mixed-citation></ref><ref id="ref-4002487091"><mixed-citation>United Kingdom Department of Health. A(H1N1) Swine Influenza: from containment to treatment. 2009 [17 October 2009]; Available from: http://www.dh.gov.uk/en/Publichealth/Flu/Swineflu/InformationandGuidance/Treatmentphase/index.htm.</mixed-citation></ref><ref id="ref-4114420138"><mixed-citation>Neuzil KM, Reed GW, Mitchel EF, Jr., Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. Jama1999 Mar 10;281(10):901-7.</mixed-citation></ref><ref id="ref-150613430"><mixed-citation>Gilsdorf A, Poggensee G. Influenza A(H1N1)v in Germany: the first 10,000 cases. Euro Surveill2009;14(34).</mixed-citation></ref><ref id="ref-3809112805"><mixed-citation>Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quinones-Falconi F, Bautista E, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med2009 Aug 13;361(7):680-9.</mixed-citation></ref><ref id="ref-669132870"><mixed-citation>Presanis AM, Lipsitch M, De Angelis D, New York City Department of Health and Mental Hygiene, Swine Flu Investigation Team, Hagy A, et al. The severity of pandemic H1N1 influenza in the United States, April &#x02013; July 2009 [Internet]. Version 22. PLoS Currents: Influenza2009;Sep 25 [revised 2009 Sep 29]:RRN1042.<pub-id pub-id-type="rrn">RRN1042</pub-id></mixed-citation></ref><ref id="ref-1521450404"><mixed-citation>Rello J, Rodriguez A, Ibanez P, Socias L, Cebrian J, Marques A, et al. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit Care2009 Sep 11;13(5):R148.</mixed-citation></ref><ref id="ref-3491413473"><mixed-citation>Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. Hospitalized Patients with 2009 H1N1 Influenza in the United States, April-June 2009. N Engl J Med 2009 Oct 8.</mixed-citation></ref><ref id="ref-336100170"><mixed-citation>Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet2000 May 27;355(9218):1845-50.</mixed-citation></ref><ref id="ref-492377043"><mixed-citation>Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. Jama2000 Feb 23;283(8):1016-24.</mixed-citation></ref><ref id="ref-156585246"><mixed-citation>Coll&#x000e8;ge des Economistes de la Sant&#x000e9; et de la Sofestec. Recommendations de bonnes pratiques des m&#x000e9;thodes d'&#x000e9;valuation &#x000e9;conomique des strat&#x000e9;gies th&#x000e9;rapeutiques. J Eco Med1997;16:329-51.</mixed-citation></ref><ref id="ref-1416903824"><mixed-citation>Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost effectiveness in health and medicine. Ed. OU Press. 1996.</mixed-citation></ref><ref id="ref-353580865"><mixed-citation>Comit&#x000e9; de lutte contre la grippe. Fiche pratique d'utilisation des antivraux pour les adultes et enfants de plus d'un an en extrahospitalier et en p&#x000e9;riode pand&#x000e9;mique. Minist&#x000e8;re charg&#x000e9; de la sant&#x000e9;; 2009 [updated 12 August 200915 October 2009].</mixed-citation></ref><ref id="ref-1898167246"><mixed-citation>Population totale par sexe, &#x000e2;ge et &#x000e9;tat matrimonial au 1er janvier 2007 [database on the Internet]2007. Available from: http://www.insee.fr/fr/ppp/bases-de-donnees/irweb/sd2006/dd/excel/sd2006_t6_fe.xls.</mixed-citation></ref><ref id="ref-1339437522"><mixed-citation>Caisse nationale de l&#x02019;Assurance-maladie des travailleurs salari&#x000e9;s. Affections de longue dur&#x000e9;e (ALD) (R&#x000e9;gime g&#x000e9;n&#x000e9;ral). Institut de Recherche et Documentation en Economie de la Sant&#x000e9;; [updated October 12, 2009]; Available from: http://www.ecosante.fr/.</mixed-citation></ref><ref id="ref-3335166991"><mixed-citation>Baker MG, Wilson N, Huang QS, Paine S, Lopez L, Bandaranayake D, et al. Pandemic influenza A(H1N1)v in New Zealand: the experience from April to August 2009. Euro Surveill2009;14(34).</mixed-citation></ref><ref id="ref-3555451527"><mixed-citation>Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med2003 Jul 28;163(14):1667-72.</mixed-citation></ref><ref id="ref-429906310"><mixed-citation>Wailoo AJ, Sutton AJ, Cooper NJ, Turner DA, Abrams KR, Brennan A, et al. Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza. Value Health2008 Mar-Apr;11(2):160-71.</mixed-citation></ref><ref id="ref-479242327"><mixed-citation>Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess2003;7(35):iii-iv, xi-xiii, 1-170.</mixed-citation></ref><ref id="ref-2471305942"><mixed-citation>Caisse nationale de l&#x02019;Assurance-maladie des travailleurs salari&#x000e9;s. Nomenclature G&#x000e9;n&#x000e9;rale des Actes Professionnels. [updated December 2008]; Available from: http://www.ameli.fr/fileadmin/user_upload/documents/NGAP-oct-2009.pdf.</mixed-citation></ref><ref id="ref-539055477"><mixed-citation>Vidal. Le dictionnaire Vidal. 2009 [17 October 2009]; Available from: http://www.vidal.fr/presse/vidal2009.pdf.</mixed-citation></ref><ref id="ref-539572061"><mixed-citation>Minist&#x000e8;re de la Sant&#x000e9;. Arr&#x000ea;t&#x000e9; du 27 juillet 1992 cr&#x000e9;ant un traitement informatique national des r&#x000e9;sum&#x000e9;s de sortie standardis&#x000e9;s et des r&#x000e9;sum&#x000e9;s standardis&#x000e9;s de facturation transmis par certains &#x000e9;tablissements hospitaliers priv&#x000e9;s conventionn&#x000e9;s relevant de l&#x02019;article L. 162- 22 du code de la s&#x000e9;curit&#x000e9; sociale.</mixed-citation></ref><ref id="ref-4265247156"><mixed-citation>Minist&#x000e8;re des Affaires Sociales et de la Solidarit&#x000e9; Nationale. Circulaire no 119 du 4/10/85 relative &#x000e0; la mise en place dans les &#x000e9;tablissements hospitaliers des R&#x000e9;sum&#x000e9;s de Sortie Standardis&#x000e9;s (RSS). Bulletin Officiel de la R&#x000e9;publique Fran&#x000e7;aise. 1985.</mixed-citation></ref><ref id="ref-415459089"><mixed-citation>Agence Technique de l'information sur l'Hospitalisation. Available from: http://www.atih.sante.fr/.</mixed-citation></ref><ref id="ref-1046517456"><mixed-citation>Minist&#x000e8;re de l&#x02019;emploi et de la solidarit&#x000e9;. &#x000c9;chelle nationale de co&#x000fb;ts relatifs par groupe homog&#x000e8;ne de malades. Edition 1999. Bulletin officiel. 1999.</mixed-citation></ref><ref id="ref-1657402311"><mixed-citation>World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th Revision. Geneva: WHO; 2007; Available from: http://apps.who.int/classifications/apps/icd/icd10online/.</mixed-citation></ref><ref id="ref-668597037"><mixed-citation>Institut de Veille Sanitaire (InVS). Point de situation au 22 septembre 2009. Bulletin grippe A (H1N1) 2009; 2009; Available from: http://www.invs.sante.fr/surveillance/grippe_dossier/points_h1n1/grippe_A_h1n1_220909/bulletin_grippe_22_09_09.pdf.</mixed-citation></ref><ref id="ref-883776861"><mixed-citation>UMR S 707 (Unit&#x000e9; Mixte de Recherche en Sant&#x000e9;), Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale (Inserm), Universit&#x000e9; Pierre et Marie Curie (UPMC). Bilan annuel du r&#x000e9;seau Sentinelles. Janvier - D&#x000e9;cembre 2007. [updated June 5, 2008]; Available from: http://websenti.b3e.jussieu.fr/sentiweb/document.php?doc=907.</mixed-citation></ref><ref id="ref-1377238325"><mixed-citation>UMR S 707 (Unit&#x000e9; Mixte de Recherche en Sant&#x000e9;), Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale (Inserm), Universit&#x000e9; Pierre et Marie Curie (UPMC). Bilan annuel du r&#x000e9;seau Sentinelles. Janvier - D&#x000e9;cembre 2008. [updated July 10, 2009]; Available from: http://websenti.b3e.jussieu.fr/sentiweb/document.php?doc=1114.</mixed-citation></ref><ref id="ref-1828640626"><mixed-citation>Lopez L, Huang QS. Influenza in New Zealand 2007. [updated March 2008]; Available from: http://www.surv.esr.cri.nz/PDF_surveillance/Virology/FluAnnRpt/InfluenzaAnn2007.pdf.</mixed-citation></ref><ref id="ref-3029952268"><mixed-citation>Lopez L, Huang QS. Influenza in New Zealand 2008. [updated March 2009]; Available from: http://www.surv.esr.cri.nz/PDF_surveillance/Virology/FluAnnRpt/InfluenzaAnn2008.pdf.</mixed-citation></ref><ref id="ref-2309517909"><mixed-citation>World Health Organization. Macroeconomics and health: investing in health for economic development. Report of the commission on macroeconomics and health. 2001 [October 7, 2008]; Available from: http://whqlibdoc.who.int/publications/2001/924154550x.pdf.</mixed-citation></ref><ref id="ref-3758611592"><mixed-citation>Critical Care Services and 2009 H1N1 Influenza in Australia and New Zealand. N Engl J Med2009 Oct 8.</mixed-citation></ref><ref id="ref-268547865"><mixed-citation>O'Brien BJ, Goeree R, Blackhouse G, Smieja M, Loeb M. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada. Value Health2003 Mar-Apr;6(2):116-25.</mixed-citation></ref><ref id="ref-3057083638"><mixed-citation>Husereau D, Brady B, McGeer A. L&#x02019;oseltamivir dans le traitement de la grippe pr&#x000e9;sum&#x000e9;e : &#x000e9;valuation clinique et &#x000e9;conomique. Rapport technologique no 21. Ottawa: Office canadien de coordination de l&#x02019;&#x000e9;valuation des technologies de la sant&#x000e9;2001.</mixed-citation></ref><ref id="ref-4255889922"><mixed-citation>Muennig PA, Khan K. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin Infect Dis2001 Dec 1;33(11):1879-85.</mixed-citation></ref><ref id="ref-2662844829"><mixed-citation>Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. Am J Med2002 Sep;113(4):300-7.</mixed-citation></ref><ref id="ref-1061940129"><mixed-citation>Lynd LD, Goeree R, O'Brien BJ. Antiviral agents for influenza: a comparison of cost-effectiveness data. Pharmacoeconomics2005;23(11):1083-106.</mixed-citation></ref><ref id="ref-1863690772"><mixed-citation>Burch J, Corbett M, Stock C, Nicholson K, Elliot AJ, Duffy S, et al. Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. Lancet Infect Dis2009 Sep;9(9):537-45.</mixed-citation></ref><ref id="ref-1307388359"><mixed-citation>Hanshaoworakul W, Simmerman JM, Narueponjirakul U, Sanasuttipun W, Shinde V, Kaewchana S, et al. Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS One2009;4(6):e6051.</mixed-citation></ref><ref id="ref-3285149995"><mixed-citation>Fordyce S, Daniels R, Hay A, Bragstad K, Abel-Nielsen S, Jensen T, et al., editors. Deep Sequencing of Oseltamivir-Resistant Pandemic Influenza A (H1N1) and Comparison to the Viral Ancestor. 49th ICAAC; September 12-15, 2009; San Francisco, CA.</mixed-citation></ref><ref id="ref-3661812639"><mixed-citation>Baz Z, Abed Y, Simon P, Hamelin M, Boivin G, editors. Impact of the Neuraminidase Mutation H274Y Conferring Resistance to Oseltamivir on the Replicative Capacity and Virulence of Different Influenza A/H1N1 Viruses. 49th ICAAC; September 12-15, 2009; San Francisco, CA.</mixed-citation></ref><ref id="ref-1999133293"><mixed-citation>Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep2009 Aug 21;58(32):893-6.</mixed-citation></ref><ref id="ref-3196184313"><mixed-citation>Harvard Opinion Research Program, Harvard School of Public Health. Public views of the H1N1 vaccine. Topline results [updated September 14-20, 2009]; Available from: http://www.hsph.harvard.edu/news/press-releases/files/H1N1_Vaccine_Topline_10.1.09.doc.</mixed-citation></ref><ref id="ref-4292333614"><mixed-citation>Haut Conseil de la sant&#x000e9; publique. Recommandations sur les priorit&#x000e9;s sanitaires d&#x02019;utilisation des vaccins pand&#x000e9;miques dirig&#x000e9;s contre le virus grippal A(H1N1)v. [updated September 7, 2009]; Available from: www.hcsp.fr/explore.cgi/avisrapports.</mixed-citation></ref><ref id="ref-2017487156"><mixed-citation>Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep2009 Aug 28;58(RR-10):1-8.</mixed-citation></ref></ref-list></back></article>